A joint effort between Leiden University’s Professor Ubbink’s lab and ZoBio’s Assay Development and Screening team has advanced fragment-based drug discovery targeting membrane proteins. Supported by a Dutch Research Council (NWO) AES grant, the project utilized protein-lipid nanodiscs to study how lipid composition affects small molecule interactions with the membrane enzyme CYP3A4.
Findings revealed that lipid types significantly influence off-target binding, underscoring the importance of lipid selection in drug screening. This research, published in Chemical Biology and Drug Design, offers valuable insights for developing therapeutics targeting complex membrane proteins
Read more here
Researchers at Leiden University Medical Center (LUMC), in collaboration with Erasmus MC and the Oncode Institute, have developed a novel vaccine targeting non-small cell lung...
Leiden University Medical Center (LUMC) has achieved a national milestone by treating the first Dutch patient with an autoimmune disease using CAR-T cell therapy. This approach,...
Leiden University Medical Center (LUMC) has successfully implemented artificial intelligence (AI) to optimize radiotherapy planning for patients with head and neck cancer. This...